(Q33407051)

English

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours (English)
Kyriakos P Papadopoulos
Joohyun Jennifer Park

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit